Opeolu Adeoye, MD a professor of emergency medicine at Washington University School of Medicine in St. Louis, led a national clinical trial that found that two anti-coagulant medications are ineffective at improving post-treatment outcomes for stroke patients.
Not for public release
This news release is embargoed until 3-Sep-2024 11:00 AM EDT
Released to reporters: 29-Aug-2024 11:00 AM EDT
A reporter's PressPass is required to
access this story until the embargo expires on 3-Sep-2024 11:00 AM EDT
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
Assistant Professor of Pharmaceutical Sciences Kuo-Ching (KC) Mei from Binghamton University, State University of New York and his team have won the $1.9M Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators (ESI) from the National Institute of General Medical Sciences to tackle gene therapy challenges.
Not for public release
This news release is embargoed until 2-Sep-2024 5:00 PM EDT
Released to reporters: 27-Aug-2024 2:00 PM EDT
A reporter's PressPass is required to
access this story until the embargo expires on 2-Sep-2024 5:00 PM EDT
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
In a landmark development for environmental conservation, a pioneering plasmonic photocatalyst has been engineered to synergistically degrade the potent pollutants hexavalent chromium (Cr(VI)) and norfloxacin from aquatic environments.
The invention of a tool capable of unlocking previously impossible organic chemical reactions has opened new pathways in the pharmaceutical industry to create effective drugs more quickly.
Since anti-obesity medications have become more widely known and prescribed, they have been touted as game-changing treatments for chronic overweight and obesity. But one common misconception about these medications is that they’re a magic bullet for better health, and it doesn’t necessarily matter what you eat when you’re taking them.
When you pick up a prescription or get a vaccination, it’s paramount that you trust the medication is safe. In the U.S., a system of laws, procedures, and personal responsibility combine to ensure drug safety, or pharmacovigilance.
EVOQ Therapeutics, Inc. (EVOQ) a biopharmaceutical company dedicated to the treatment of autoimmune diseases, announced today the receipt of a $2 million grant from the National Institutes of Health (NIH) to advance novel therapies for autoimmune diseases.
When taken at the first signs of a migraine, before headache pain begins, a drug called ubrogepant may be effective in helping people with migraine go about their daily lives with little or no symptoms, according to a new study published in the August 28, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A proposed artificial intelligence tool to support clinician decision-making about hospital patients at risk for sepsis has an unusual feature: accounting for its lack of certainty and suggesting what demographic data, vital signs and lab test results it needs to improve its predictive performance.
Scientists have developed a new method for crafting intricate microfluidic channels in glass using intense laser pulses. These tiny channels offer exceptional clarity for ultraviolet (UV) light, making them ideal for continuous-flow photochemical reactions like synthesising vitamin D3. The technique paves the way for miniaturized, efficient chemical production methods with promising applications in medicine, materials science, and beyond.
Nearly half of counties in the United States have at least one ‘pharmacy desert’ where there is no retail pharmacy within 10 miles, according to a new study published by researchers at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Research Institute (OSUCCC – James).
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (ClinicalTrials.gov Identifier: NCT06565611).
A recent publication outlines consensus recommendations on several aspects of managing epilepsy with eyelid myoclonia, also known as Jeavons syndrome. What are the most effective first-line medications? Are there non-pharmacologic treatment options? Can people with this type of epilepsy drive safely? Dr. Alina Ivaniuk talks to the paper’s first author, Dr. Kelsey Smith.
Scientists are finding clues for how to treat diabetes and hormone disorders in an unexpected place: a toxin from one of the most venomous animals on the planet.
Moffitt Cancer Center researchers have developed a novel reagent that enhances the precision of drug synthesis. This innovative method, published in Nature Communications, introduces a new sulfur fluoride exchange (SuFEx) reagent that allows for highly controlled production of crucial sulfur-based molecules, including sulfinamides, sulfonimidamides and sulfoximines.